Seeking Alpha Portfolio App for iPad
Dividends & Income
View as an RSS Feed
View XURE's Comments
Star Scientific And TherapeuticsMD: 2 Overvalued Pseudo-Pharmaceuticals
"High borrow rates are not caused by naked shorts. Naked shorts have been outlawed since 2005, and as a practitioner, if they do exist from certain broker-dealers, are quickly covered in the market. Thus,naked shorts do not cause high borrow rates."
Ed, are you saying you are a practitioner of naked shorting, which as you explain is against the law?
Amazing how naked shorting is outlawed and you say "if they do exist", are quickly covered in the market. How comes you know so much about this illegal activity and just so happen to write an article that falls perfect into a STSI short selling position and those who may illegally short selling this stock?, which again can't exist because it is unlawful. Who are you kidding?
Naked shorting is one of the biggest evils in the biotech research market place. Many small biotechs with viable potentials have their PPS deflated due to this American greed "unlawful" strategy to make money, which mitigates capital during secondary offerings and shortens runway for major advancement against fighting diseases to mention two huge negatives.
Clearly your article is biased on the short side and slip or not (about practicing naked short selling), you know way too much about naked short selling that has been "outlawed since 2005". As I read the article, it basically confirms that naked short selling exists, which falls into "American Greed" folk who would prefer biotech companies like STSI to fail as opposed to participating in the advancement of fighting inflammation, thyroiditis and Azlheimer's disease.
All naked short sellers committing this illegal practice, should be stopped. In biotech industry, I feel they are scum bags who prefer to help a biotech company fail, and make money while doing it, against the advancement of medicine.
I can't help think about this when reading your biased short article.
Dec 23 04:27 PM
Link to Comment
Dendreon: Fear is Our Friend
As a group health actuary, I followed the Provenge saga and its amazing the incorrect information that comes from the so called experts. The 14.2 month survival against the true placebo group is compelling. Excellent article on the real deal.
Provenge is the real deal and I hope CMS does nothing to complicate nor delay this FDA approved drug that has met the highest of safety and efficacy standards through FDA's SPA.
End stage prostate cancer patients have been waiting for this higher quality, safer and more effective drug than existing chemotherapy option. Male Provenge candidates have been funding Medicare their entire working lifetime and now is the time for CMS to support their need at this terrible time of advanced prostate cancer.
FDA put Dendreon and end stage prostate cancer patients through a long and rigorous process. CMS clarification needs to be positive for continuity of administration across the United States and not whatsoever induce fear for Medicare eligibles who are dealign with this prevalent disease. 14.2 months of survival w/o the adverse affects (and costs of these adverse affects) of toxic chemotherapy is compelling.
Jul 7 05:49 PM
Link to Comment
The Opinion Leaders
Xignite quote data
© 2013 Seeking Alpha